Corbus Pharmaceuticals
CRBP
105 hedge funds and large institutions have $168M invested in Corbus Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 33 increasing their positions, 26 reducing their positions, and 13 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
27% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 26
9% more capital invested
Capital invested by funds: $155M → $168M (+$13.5M)
2% more funds holding
Funds holding: 103 → 105 (+2)
0.05% less ownership
Funds ownership: 1.64% → 1.59% (-0.05%)
62% less call options, than puts
Call options by funds: $587K | Put options by funds: $1.54M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.45M |
| 2 |
JP Morgan Chase
New York
|
+$700K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$393K |
| 4 |
GAI
General American Investors
New York
|
+$369K |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
+$339K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$5.47M |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$2.32M |
| 3 |
SC
Sculptor Capital
New York
|
-$681K |
| 4 |
AA
ALPS Advisors
Denver,
Colorado
|
-$628K |
| 5 |
Morgan Stanley
New York
|
-$585K |
CRBP Hedge Fund Activity: Q4 2019 in Review
105 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q4 2019, worth a combined $168M — up 8.7% from $155M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CRBP positions and 13 closed out — a net gain of 4 holders — while 33 added to existing stakes and 26 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $1.45M. The largest seller was ETF Managers Group, cutting an estimated $5.47M.
- 105 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q4 2019, up from 103 in Q3 2019.
- Funds reported $168M of Corbus Pharmaceuticals stock for Q4 2019, up 8.7% quarter-over-quarter.
- 17 funds opened new Corbus Pharmaceuticals positions in Q4 2019 and 13 closed out, a net change of +4 holders.
- The largest Corbus Pharmaceuticals buyer in Q4 2019 was Susquehanna International Group, an estimated $1.45M added.
- The largest Corbus Pharmaceuticals seller in Q4 2019 was ETF Managers Group, an estimated $5.47M sold.
Based on aggregated 13F filings for Q4 2019.